|
KMID : 1141320220370010018
|
|
Kosin Medical Journal
2022 Volume.37 No. 1 p.18 ~ p.26
|
|
|
Adverse events following vaccination against coronavirus disease 2019
|
|
Jeon Min-Ji
Jin Sol
Lee Jin-Young
|
|
|
Abstract
|
|
|
|
To overcome the coronavirus disease 2019 (COVID-19) pandemic, large-scale vaccination is proceeding worldwide. As of December 23, 2021, 10 novel vaccines against COVID-19 had been validated for use by the World Health Organization (WHO), including BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), AZD1222 (AstraZeneca), and Ad26.COV2.S (Janssen). These novel vaccines against COVID-19 showed acceptable safety profiles in randomized clinical trials. Most adverse events following immunization (AEFIs) associated with these novel vaccines ranged from mild to moderate and improved within a few days after administration. However, serious adverse events associated with vaccines that were not observed in the clinical trials were reported in real-world data. Adverse events of special interest include not only anaphylaxis or neurologic disorders (such as Guillain-Barre syndrome, transverse myelitis, or seizure) but also myocarditis or pericarditis associated with the messenger RNA (mRNA) vaccines and thrombosis with thrombocytopenia syndrome associated with the adenovirus-vector vaccines. Although several fatal cases of serious AEFIs that may have been related to vaccination have been reported, it is recommended to continue vaccination because the benefits of vaccines’ preventive effects against COVID-19 outweigh the risks of rare serious adverse events. Long-term monitoring of various AEFIs and sharing of clinical experiences are necessary for safe and efficient large-scale vaccination.
|
|
|
KEYWORD
|
|
|
Adverse drug events, COVID-19, Vaccination
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|